8-K

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 7, 2019

BioMarin Pharmaceutical Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware	000-26727	68-0397820
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
770 Lindaro Street, San Rafael, California		94901
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (415) 506-6700

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02 Results of Operations and Financial Condition.

On January 7, 2019, BioMarin Pharmaceutical Inc. (the “Company”) provided a business update, including updated financial guidance for 2018, at the 37th Annual J.P. Morgan Healthcare Conference, which presentation was previously announced by press release and was available via simultaneous webcast. A copy of the relevant slides relating to the aforementioned financial update is attached hereto as Exhibit 99.1 and incorporated by reference herein.

The information in this Form 8-K, including the attached exhibit, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description.
99.1	Slides from BioMarin Pharmaceutical Inc. J.P. Morgan 2019 Presentation, dated January 7, 2019.

Forward Looking Statements

This current report on Form 8-K contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including financial guidance for 2018. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: results and timing of current and planned preclinical studies and clinical trials of our product candidates, the continued clinical experiences of the patients in the current clinical studies; the content and timing of decisions by the FDA, the European Commission and other regulatory authorities; and those factors detailed in BioMarin’s filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption “Risk Factors” in BioMarin’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 as such factors may be updated by any subsequent reports. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BioMarin Pharmaceutical Inc., a Delaware corporation
Date: January 8, 2019	By:	/s/ G. Eric Davis
		G. Eric Davis Executive Vice President, General Counsel

EX-99.1

Exhibit 99.1 th 37 Annual J.P. Morgan Healthcare Conference Jean-Jacques Bienaimé Chairman and Chief Executive Officer BioMarin Pharmaceutical Inc. 2019 Exhibit 99.1 th 37 Annual J.P. Morgan Healthcare Conference Jean-Jacques Bienaimé Chairman and Chief Executive Officer BioMarin Pharmaceutical Inc. 2019

Safe Harbor Statement This non-confidential presentation contains‘forward-looking statements’about the business prospects of BioMarin Pharmaceutical Inc., including potential future products in different areas of therapeutic research and development. Results may differ materially depending on the progress of BioMarin’s product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market and developments by competitors, and those factors detailed in BioMarin’s filings with the Securities and Exchange Commission such as 10-Q, 10-K and 8-K reports. 2Safe Harbor Statement This non-confidential presentation contains‘forward-looking statements’about the business prospects of BioMarin Pharmaceutical Inc., including potential future products in different areas of therapeutic research and development. Results may differ materially depending on the progress of BioMarin’s product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market and developments by competitors, and those factors detailed in BioMarin’s filings with the Securities and Exchange Commission such as 10-Q, 10-K and 8-K reports. 2

2018 Final Financial Guidance Largely in-line with Prior Guidance Reaffirmed Y/Y revenue growth of approximately 15% through 2020; $2B in 2020 Revenue Guidance ($ in millions) Item 2018 Guidance Final 2018 Guidance Total BioMarin Revenues $1,470 to $1,530 Unchanged Vimizim Net Product Revenue $460 to $500 Unchanged Naglazyme Net Product Revenue $325 to $355 Unchanged Kuvan Net Product Revenue $440 to $480 $430 to $450 Brineura Net Product Revenue $35 to $55 Unchanged Palynziq Net Product Revenue $10 to $14 Unchanged Selected Income Statement Guidance ($ in millions, except percentages) Item 2018 Guidance Cost of Sales (% of Total Revenue) 20.0% to 21.0% 20.25% to 21.25% SG&A Expense $575 to $615 Unchanged R&D Expense $680 to $710 Unchanged Non-GAAP Net Income $100 to $140 $90 to $105 GAAP Net Loss $(115) to $(165) $(100) to $(115) All Financial Guidance items are calculated based on Generally Accepted Accounting Principles (GAAP) with the exception of Non-GAAP Income. Refer to Non-GAAP Information beginning on page 10 of this press release for a complete discussion of 29 the Company's Non-GAAP financial information and reconciliations to the comparable GAAP reported information.2018 Final Financial Guidance Largely in-line with Prior Guidance Reaffirmed Y/Y revenue growth of approximately 15% through 2020; $2B in 2020 Revenue Guidance ($ in millions) Item 2018 Guidance Final 2018 Guidance Total BioMarin Revenues $1,470 to $1,530 Unchanged Vimizim Net Product Revenue $460 to $500 Unchanged Naglazyme Net Product Revenue $325 to $355 Unchanged Kuvan Net Product Revenue $440 to $480 $430 to $450 Brineura Net Product Revenue $35 to $55 Unchanged Palynziq Net Product Revenue $10 to $14 Unchanged Selected Income Statement Guidance ($ in millions, except percentages) Item 2018 Guidance Cost of Sales (% of Total Revenue) 20.0% to 21.0% 20.25% to 21.25% SG&A Expense $575 to $615 Unchanged R&D Expense $680 to $710 Unchanged Non-GAAP Net Income $100 to $140 $90 to $105 GAAP Net Loss $(115) to $(165) $(100) to $(115) All Financial Guidance items are calculated based on Generally Accepted Accounting Principles (GAAP) with the exception of Non-GAAP Income. Refer to Non-GAAP Information beginning on page 10 of this press release for a complete discussion of 29 the Company's Non-GAAP financial information and reconciliations to the comparable GAAP reported information.